Asset profile
Ponesimod
Small molecule
Evidence outlook
Approved: Multiple Sclerosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Psoriasis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
107 competitors in this universe: 4 direct rivals (same mechanism and indication), 3 same-class, 100 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ponesimod: this drug | Approved | Small molecule | S1P receptor | ||
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | ||
| Mayzent | Approved | Small molecule | S1P receptor | ||
| Ozanimod (Zeposia) | Approved | Small molecule | S1P receptor | ||
| Tascenso ODT | Approved | Small molecule | S1P receptor | ||
| Etrasimod (Velsipity) | Approved | Small molecule | S1P receptor | ||
| Amiselimod | Phase 2 | Small molecule | S1P receptor | ||
| Tamuzimod | Phase 2 | Small molecule | S1P receptor | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| Brodalumab (Siliq) | Approved | Monoclonal antibody | IL-17 receptor A |
…and 92 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.